Amgen's US$2.5 billion acquisition of Teneobio: Acquired dual/multispecific antibody technology platform + new T cell adapter platform!

Bi/multispecific antibody & T cell adapter

July 28, 2021/Bio Valley BIOON/ --Amgen (Amgen) and Teneobio recently announced an agreement to acquire them
.

According to the agreement, Amgen will acquire Teneobio, a privately held clinical stage biotechnology company that is developing a new class of biological agents called Human Heavy-Chain Antibodies

The acquisition includes Teneobio’s proprietary bispecific and multispecific antibody technology, which will greatly accelerate and increase the efficiency of the discovery and development of new molecules that have the potential to treat a wide range of important diseases in Amgen’s core therapeutic areas
.

These platforms will complement Amgen’s existing antibody capabilities by adding a heavy chain platform that allows for a simplified, sequence-based discovery method for target binders

The acquisition will also bring TNB-585 (a bispecific T cell adaptor in phase 1 clinical development for the treatment of metastatic castration-resistant prostate cancer [mCRPC]), as well as some preclinical tumor pipeline assets.
The asset has the potential to submit a clinical trial application (IND) in the near future
.

TNB-585 complements Amgen’s existing prostate cancer portfolio, which includes acapatamab (formerly known as AMG 160) and AMG 509.

Teneobio's pipeline assets (click on the image to see a larger image)

Dr.

David M.
Reese, Executive Vice President of Amgen R&D, said: "The acquisition of Teneobio will strengthen our ability to develop innovative drugs, treat patients with severe diseases, and bring best-in-class products to the market, especially It is a multi-specific and bi-specific drug for a wide range of disease targets in our core therapeutic areas.

Dr.

Roland Buelow, Chief Executive Officer of Teneobio, said: “The Teneobio team is keen to join forces with

In June 2021, AbbVie exercised its rights to acquire TeneoOne (a subsidiary of Teneobio), including a lead asset TNB-383B, which is an anti-CD3/BCMA bispecific for the treatment of relapsed or refractory multiple myeloma For sex drugs, the objective response rate (ORR) in the phase 1 clinical study was as high as 79%
.

Before the end of the Amgen acquisition, Teneobio’s three subsidiaries will be split to Teneobio’s existing shareholders: TeneoTwo (anti-CD19/CD3), TeneoFour (anti-CD38 enzyme inhibitor), TeneoTen (anti-HBV/CD3)
.

The acquisition is subject to customary delivery conditions, including applicable regulatory approvals, and is expected to be completed in the second half of 2021

Original source: Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments